Unveiling the disparity in access to cancer therapies: A cross-sectional study on FDA-approved drugs in India
South Asian Journal of Cancer · 18.05.2026 · 15 · 19-23
DOI: 10.25259/sajc_15_2025 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift South Asian Journal of Cancer, online erschienen am 18.05.2026. Verfasst von Anuradha Mehta und 4 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Despite significant advancements in global oncology care, many U.S. Food and Drug Administration (FDA) approved drugs with high European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMOMCBS) scores are unavailable in India. These drugs have the potential to revolutionize cancer treatment, but face challenges related to regulatory frameworks, economic barriers, insurance coverage, and healthcare infrastructure. This article explores these barriers and their impact on cancer healthcare in India while proposing actionable solutions to address them.
Zitieren
APA
Mehta, A., Nayak, L., Noronha, V., Prabhash, K., & Banavali, S. (2026). Unveiling the disparity in access to cancer therapies: A cross-sectional study on FDA-approved drugs in India. South Asian Journal of Cancer, 15, 19-23. https://doi.org/10.25259/sajc_15_2025
Vancouver
Mehta A, Nayak L, Noronha V, Prabhash K, Banavali S. Unveiling the disparity in access to cancer therapies: A cross-sectional study on FDA-approved drugs in India. South Asian Journal of Cancer. 2026;15:19-23. doi:10.25259/sajc_15_2025
BibTeX
@article{Mehta2026,
author = {Mehta, Anuradha and Nayak, Lingaraj and Noronha, Vanita and Prabhash, Kumar and Banavali, Shripad},
title = {Unveiling the disparity in access to cancer therapies: A cross-sectional study on FDA-approved drugs in India},
journal = {South Asian Journal of Cancer},
year = {2026},
volume = {15},
pages = {19--23},
doi = {10.25259/sajc_15_2025}
}
EUVIMED